Research ArticleArticle
Efficacy and Safety of Pregabalin in Patients with Fibromyalgia and Comorbid Depression Taking Concurrent Antidepressant Medication: A Randomized, Placebo-controlled Study
Lesley M. Arnold, Piercarlo Sarzi-Puttini, Pierre Arsenault, Tahira Khan, Pritha Bhadra Brown, Andrew Clair, Joseph M. Scavone, Joseph Driscoll, Jaren Landen and Lynne Pauer
The Journal of Rheumatology June 2015, jrheum.141196; DOI: https://doi.org/10.3899/jrheum.141196
Lesley M. Arnold
From the Women’s Health Research Program, University of Cincinnati College of Medicine, Cincinnati, Ohio; Pfizer Inc., Groton, Connecticut; Pfizer Inc., New York, New York, USA; Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco, Milan, Italy; Family Medicine Department, University of Sherbrooke, Sherbrooke, Quebec, Canada. Sponsored by Pfizer Inc. Dr. Arnold has received consultancy and speaking fees from Pfizer Inc. (≥ $10,000). Dr. Sarzi-Puttini has received consulting fees, speaking fees, and/or honoraria from Pfizer Inc. Dr. Arsenault has received research funding from and/or participated in a speakers’ bureau for Pfizer Inc. Joseph Driscoll was an employee of inVentiv Health Clinical, which is a paid contractor to Pfizer Inc. for the management of the study and the development of this manuscript. Tahira Khan, Pritha Bhadra Brown, Andrew Clair, Joseph M. Scavone, Joseph Driscoll, Jaren Landen, and Lynne Pauer are fulltime employees of Pfizer Inc. and have stock options with the company. L.M. Arnold, MD, Professor of Psychiatry and Behavioral Neuroscience and Director, Women’s Health Research Program, University of Cincinnati College of Medicine; P. Sarzi-Puttini, MD, Direttore presso U.O.C., Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco; P. Arsenault, MD, Associate Professor, Family Medicine Department, University of Sherbrooke; T. Khan, MD, Senior Manager Clinician, Clinical Sciences, Pfizer Inc.; P. Bhadra Brown, PhD, Director, Statistics, Pfizer Inc.; A. Clair, PhD, Senior Medical Director, US Medical Affairs, Pfizer Inc.; J.M. Scavone, PharmD, Senior Director; J. Driscoll, PharmD, Director; J. Landen, PhD, Director; L. Pauer, MS, Senior Director, Clinical Sciences, Pfizer Inc. Address correspondence to Dr. L.M. Arnold, University of Cincinnati College of Medicine, 260 Stetson St., Suite 3200, Cincinnati, Ohio 45219, USA. E-mail: arnoldlm@ucmail.uc.edu. Accepted for publication March 26, 2015.
Piercarlo Sarzi-Puttini
From the Women’s Health Research Program, University of Cincinnati College of Medicine, Cincinnati, Ohio; Pfizer Inc., Groton, Connecticut; Pfizer Inc., New York, New York, USA; Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco, Milan, Italy; Family Medicine Department, University of Sherbrooke, Sherbrooke, Quebec, Canada. Sponsored by Pfizer Inc. Dr. Arnold has received consultancy and speaking fees from Pfizer Inc. (≥ $10,000). Dr. Sarzi-Puttini has received consulting fees, speaking fees, and/or honoraria from Pfizer Inc. Dr. Arsenault has received research funding from and/or participated in a speakers’ bureau for Pfizer Inc. Joseph Driscoll was an employee of inVentiv Health Clinical, which is a paid contractor to Pfizer Inc. for the management of the study and the development of this manuscript. Tahira Khan, Pritha Bhadra Brown, Andrew Clair, Joseph M. Scavone, Joseph Driscoll, Jaren Landen, and Lynne Pauer are fulltime employees of Pfizer Inc. and have stock options with the company. L.M. Arnold, MD, Professor of Psychiatry and Behavioral Neuroscience and Director, Women’s Health Research Program, University of Cincinnati College of Medicine; P. Sarzi-Puttini, MD, Direttore presso U.O.C., Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco; P. Arsenault, MD, Associate Professor, Family Medicine Department, University of Sherbrooke; T. Khan, MD, Senior Manager Clinician, Clinical Sciences, Pfizer Inc.; P. Bhadra Brown, PhD, Director, Statistics, Pfizer Inc.; A. Clair, PhD, Senior Medical Director, US Medical Affairs, Pfizer Inc.; J.M. Scavone, PharmD, Senior Director; J. Driscoll, PharmD, Director; J. Landen, PhD, Director; L. Pauer, MS, Senior Director, Clinical Sciences, Pfizer Inc. Address correspondence to Dr. L.M. Arnold, University of Cincinnati College of Medicine, 260 Stetson St., Suite 3200, Cincinnati, Ohio 45219, USA. E-mail: arnoldlm@ucmail.uc.edu. Accepted for publication March 26, 2015.
Pierre Arsenault
From the Women’s Health Research Program, University of Cincinnati College of Medicine, Cincinnati, Ohio; Pfizer Inc., Groton, Connecticut; Pfizer Inc., New York, New York, USA; Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco, Milan, Italy; Family Medicine Department, University of Sherbrooke, Sherbrooke, Quebec, Canada. Sponsored by Pfizer Inc. Dr. Arnold has received consultancy and speaking fees from Pfizer Inc. (≥ $10,000). Dr. Sarzi-Puttini has received consulting fees, speaking fees, and/or honoraria from Pfizer Inc. Dr. Arsenault has received research funding from and/or participated in a speakers’ bureau for Pfizer Inc. Joseph Driscoll was an employee of inVentiv Health Clinical, which is a paid contractor to Pfizer Inc. for the management of the study and the development of this manuscript. Tahira Khan, Pritha Bhadra Brown, Andrew Clair, Joseph M. Scavone, Joseph Driscoll, Jaren Landen, and Lynne Pauer are fulltime employees of Pfizer Inc. and have stock options with the company. L.M. Arnold, MD, Professor of Psychiatry and Behavioral Neuroscience and Director, Women’s Health Research Program, University of Cincinnati College of Medicine; P. Sarzi-Puttini, MD, Direttore presso U.O.C., Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco; P. Arsenault, MD, Associate Professor, Family Medicine Department, University of Sherbrooke; T. Khan, MD, Senior Manager Clinician, Clinical Sciences, Pfizer Inc.; P. Bhadra Brown, PhD, Director, Statistics, Pfizer Inc.; A. Clair, PhD, Senior Medical Director, US Medical Affairs, Pfizer Inc.; J.M. Scavone, PharmD, Senior Director; J. Driscoll, PharmD, Director; J. Landen, PhD, Director; L. Pauer, MS, Senior Director, Clinical Sciences, Pfizer Inc. Address correspondence to Dr. L.M. Arnold, University of Cincinnati College of Medicine, 260 Stetson St., Suite 3200, Cincinnati, Ohio 45219, USA. E-mail: arnoldlm@ucmail.uc.edu. Accepted for publication March 26, 2015.
Tahira Khan
From the Women’s Health Research Program, University of Cincinnati College of Medicine, Cincinnati, Ohio; Pfizer Inc., Groton, Connecticut; Pfizer Inc., New York, New York, USA; Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco, Milan, Italy; Family Medicine Department, University of Sherbrooke, Sherbrooke, Quebec, Canada. Sponsored by Pfizer Inc. Dr. Arnold has received consultancy and speaking fees from Pfizer Inc. (≥ $10,000). Dr. Sarzi-Puttini has received consulting fees, speaking fees, and/or honoraria from Pfizer Inc. Dr. Arsenault has received research funding from and/or participated in a speakers’ bureau for Pfizer Inc. Joseph Driscoll was an employee of inVentiv Health Clinical, which is a paid contractor to Pfizer Inc. for the management of the study and the development of this manuscript. Tahira Khan, Pritha Bhadra Brown, Andrew Clair, Joseph M. Scavone, Joseph Driscoll, Jaren Landen, and Lynne Pauer are fulltime employees of Pfizer Inc. and have stock options with the company. L.M. Arnold, MD, Professor of Psychiatry and Behavioral Neuroscience and Director, Women’s Health Research Program, University of Cincinnati College of Medicine; P. Sarzi-Puttini, MD, Direttore presso U.O.C., Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco; P. Arsenault, MD, Associate Professor, Family Medicine Department, University of Sherbrooke; T. Khan, MD, Senior Manager Clinician, Clinical Sciences, Pfizer Inc.; P. Bhadra Brown, PhD, Director, Statistics, Pfizer Inc.; A. Clair, PhD, Senior Medical Director, US Medical Affairs, Pfizer Inc.; J.M. Scavone, PharmD, Senior Director; J. Driscoll, PharmD, Director; J. Landen, PhD, Director; L. Pauer, MS, Senior Director, Clinical Sciences, Pfizer Inc. Address correspondence to Dr. L.M. Arnold, University of Cincinnati College of Medicine, 260 Stetson St., Suite 3200, Cincinnati, Ohio 45219, USA. E-mail: arnoldlm@ucmail.uc.edu. Accepted for publication March 26, 2015.
Pritha Bhadra Brown
From the Women’s Health Research Program, University of Cincinnati College of Medicine, Cincinnati, Ohio; Pfizer Inc., Groton, Connecticut; Pfizer Inc., New York, New York, USA; Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco, Milan, Italy; Family Medicine Department, University of Sherbrooke, Sherbrooke, Quebec, Canada. Sponsored by Pfizer Inc. Dr. Arnold has received consultancy and speaking fees from Pfizer Inc. (≥ $10,000). Dr. Sarzi-Puttini has received consulting fees, speaking fees, and/or honoraria from Pfizer Inc. Dr. Arsenault has received research funding from and/or participated in a speakers’ bureau for Pfizer Inc. Joseph Driscoll was an employee of inVentiv Health Clinical, which is a paid contractor to Pfizer Inc. for the management of the study and the development of this manuscript. Tahira Khan, Pritha Bhadra Brown, Andrew Clair, Joseph M. Scavone, Joseph Driscoll, Jaren Landen, and Lynne Pauer are fulltime employees of Pfizer Inc. and have stock options with the company. L.M. Arnold, MD, Professor of Psychiatry and Behavioral Neuroscience and Director, Women’s Health Research Program, University of Cincinnati College of Medicine; P. Sarzi-Puttini, MD, Direttore presso U.O.C., Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco; P. Arsenault, MD, Associate Professor, Family Medicine Department, University of Sherbrooke; T. Khan, MD, Senior Manager Clinician, Clinical Sciences, Pfizer Inc.; P. Bhadra Brown, PhD, Director, Statistics, Pfizer Inc.; A. Clair, PhD, Senior Medical Director, US Medical Affairs, Pfizer Inc.; J.M. Scavone, PharmD, Senior Director; J. Driscoll, PharmD, Director; J. Landen, PhD, Director; L. Pauer, MS, Senior Director, Clinical Sciences, Pfizer Inc. Address correspondence to Dr. L.M. Arnold, University of Cincinnati College of Medicine, 260 Stetson St., Suite 3200, Cincinnati, Ohio 45219, USA. E-mail: arnoldlm@ucmail.uc.edu. Accepted for publication March 26, 2015.
Andrew Clair
From the Women’s Health Research Program, University of Cincinnati College of Medicine, Cincinnati, Ohio; Pfizer Inc., Groton, Connecticut; Pfizer Inc., New York, New York, USA; Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco, Milan, Italy; Family Medicine Department, University of Sherbrooke, Sherbrooke, Quebec, Canada. Sponsored by Pfizer Inc. Dr. Arnold has received consultancy and speaking fees from Pfizer Inc. (≥ $10,000). Dr. Sarzi-Puttini has received consulting fees, speaking fees, and/or honoraria from Pfizer Inc. Dr. Arsenault has received research funding from and/or participated in a speakers’ bureau for Pfizer Inc. Joseph Driscoll was an employee of inVentiv Health Clinical, which is a paid contractor to Pfizer Inc. for the management of the study and the development of this manuscript. Tahira Khan, Pritha Bhadra Brown, Andrew Clair, Joseph M. Scavone, Joseph Driscoll, Jaren Landen, and Lynne Pauer are fulltime employees of Pfizer Inc. and have stock options with the company. L.M. Arnold, MD, Professor of Psychiatry and Behavioral Neuroscience and Director, Women’s Health Research Program, University of Cincinnati College of Medicine; P. Sarzi-Puttini, MD, Direttore presso U.O.C., Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco; P. Arsenault, MD, Associate Professor, Family Medicine Department, University of Sherbrooke; T. Khan, MD, Senior Manager Clinician, Clinical Sciences, Pfizer Inc.; P. Bhadra Brown, PhD, Director, Statistics, Pfizer Inc.; A. Clair, PhD, Senior Medical Director, US Medical Affairs, Pfizer Inc.; J.M. Scavone, PharmD, Senior Director; J. Driscoll, PharmD, Director; J. Landen, PhD, Director; L. Pauer, MS, Senior Director, Clinical Sciences, Pfizer Inc. Address correspondence to Dr. L.M. Arnold, University of Cincinnati College of Medicine, 260 Stetson St., Suite 3200, Cincinnati, Ohio 45219, USA. E-mail: arnoldlm@ucmail.uc.edu. Accepted for publication March 26, 2015.
Joseph M. Scavone
From the Women’s Health Research Program, University of Cincinnati College of Medicine, Cincinnati, Ohio; Pfizer Inc., Groton, Connecticut; Pfizer Inc., New York, New York, USA; Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco, Milan, Italy; Family Medicine Department, University of Sherbrooke, Sherbrooke, Quebec, Canada. Sponsored by Pfizer Inc. Dr. Arnold has received consultancy and speaking fees from Pfizer Inc. (≥ $10,000). Dr. Sarzi-Puttini has received consulting fees, speaking fees, and/or honoraria from Pfizer Inc. Dr. Arsenault has received research funding from and/or participated in a speakers’ bureau for Pfizer Inc. Joseph Driscoll was an employee of inVentiv Health Clinical, which is a paid contractor to Pfizer Inc. for the management of the study and the development of this manuscript. Tahira Khan, Pritha Bhadra Brown, Andrew Clair, Joseph M. Scavone, Joseph Driscoll, Jaren Landen, and Lynne Pauer are fulltime employees of Pfizer Inc. and have stock options with the company. L.M. Arnold, MD, Professor of Psychiatry and Behavioral Neuroscience and Director, Women’s Health Research Program, University of Cincinnati College of Medicine; P. Sarzi-Puttini, MD, Direttore presso U.O.C., Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco; P. Arsenault, MD, Associate Professor, Family Medicine Department, University of Sherbrooke; T. Khan, MD, Senior Manager Clinician, Clinical Sciences, Pfizer Inc.; P. Bhadra Brown, PhD, Director, Statistics, Pfizer Inc.; A. Clair, PhD, Senior Medical Director, US Medical Affairs, Pfizer Inc.; J.M. Scavone, PharmD, Senior Director; J. Driscoll, PharmD, Director; J. Landen, PhD, Director; L. Pauer, MS, Senior Director, Clinical Sciences, Pfizer Inc. Address correspondence to Dr. L.M. Arnold, University of Cincinnati College of Medicine, 260 Stetson St., Suite 3200, Cincinnati, Ohio 45219, USA. E-mail: arnoldlm@ucmail.uc.edu. Accepted for publication March 26, 2015.
Joseph Driscoll
From the Women’s Health Research Program, University of Cincinnati College of Medicine, Cincinnati, Ohio; Pfizer Inc., Groton, Connecticut; Pfizer Inc., New York, New York, USA; Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco, Milan, Italy; Family Medicine Department, University of Sherbrooke, Sherbrooke, Quebec, Canada. Sponsored by Pfizer Inc. Dr. Arnold has received consultancy and speaking fees from Pfizer Inc. (≥ $10,000). Dr. Sarzi-Puttini has received consulting fees, speaking fees, and/or honoraria from Pfizer Inc. Dr. Arsenault has received research funding from and/or participated in a speakers’ bureau for Pfizer Inc. Joseph Driscoll was an employee of inVentiv Health Clinical, which is a paid contractor to Pfizer Inc. for the management of the study and the development of this manuscript. Tahira Khan, Pritha Bhadra Brown, Andrew Clair, Joseph M. Scavone, Joseph Driscoll, Jaren Landen, and Lynne Pauer are fulltime employees of Pfizer Inc. and have stock options with the company. L.M. Arnold, MD, Professor of Psychiatry and Behavioral Neuroscience and Director, Women’s Health Research Program, University of Cincinnati College of Medicine; P. Sarzi-Puttini, MD, Direttore presso U.O.C., Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco; P. Arsenault, MD, Associate Professor, Family Medicine Department, University of Sherbrooke; T. Khan, MD, Senior Manager Clinician, Clinical Sciences, Pfizer Inc.; P. Bhadra Brown, PhD, Director, Statistics, Pfizer Inc.; A. Clair, PhD, Senior Medical Director, US Medical Affairs, Pfizer Inc.; J.M. Scavone, PharmD, Senior Director; J. Driscoll, PharmD, Director; J. Landen, PhD, Director; L. Pauer, MS, Senior Director, Clinical Sciences, Pfizer Inc. Address correspondence to Dr. L.M. Arnold, University of Cincinnati College of Medicine, 260 Stetson St., Suite 3200, Cincinnati, Ohio 45219, USA. E-mail: arnoldlm@ucmail.uc.edu. Accepted for publication March 26, 2015.
Jaren Landen
From the Women’s Health Research Program, University of Cincinnati College of Medicine, Cincinnati, Ohio; Pfizer Inc., Groton, Connecticut; Pfizer Inc., New York, New York, USA; Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco, Milan, Italy; Family Medicine Department, University of Sherbrooke, Sherbrooke, Quebec, Canada. Sponsored by Pfizer Inc. Dr. Arnold has received consultancy and speaking fees from Pfizer Inc. (≥ $10,000). Dr. Sarzi-Puttini has received consulting fees, speaking fees, and/or honoraria from Pfizer Inc. Dr. Arsenault has received research funding from and/or participated in a speakers’ bureau for Pfizer Inc. Joseph Driscoll was an employee of inVentiv Health Clinical, which is a paid contractor to Pfizer Inc. for the management of the study and the development of this manuscript. Tahira Khan, Pritha Bhadra Brown, Andrew Clair, Joseph M. Scavone, Joseph Driscoll, Jaren Landen, and Lynne Pauer are fulltime employees of Pfizer Inc. and have stock options with the company. L.M. Arnold, MD, Professor of Psychiatry and Behavioral Neuroscience and Director, Women’s Health Research Program, University of Cincinnati College of Medicine; P. Sarzi-Puttini, MD, Direttore presso U.O.C., Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco; P. Arsenault, MD, Associate Professor, Family Medicine Department, University of Sherbrooke; T. Khan, MD, Senior Manager Clinician, Clinical Sciences, Pfizer Inc.; P. Bhadra Brown, PhD, Director, Statistics, Pfizer Inc.; A. Clair, PhD, Senior Medical Director, US Medical Affairs, Pfizer Inc.; J.M. Scavone, PharmD, Senior Director; J. Driscoll, PharmD, Director; J. Landen, PhD, Director; L. Pauer, MS, Senior Director, Clinical Sciences, Pfizer Inc. Address correspondence to Dr. L.M. Arnold, University of Cincinnati College of Medicine, 260 Stetson St., Suite 3200, Cincinnati, Ohio 45219, USA. E-mail: arnoldlm@ucmail.uc.edu. Accepted for publication March 26, 2015.
Lynne Pauer
From the Women’s Health Research Program, University of Cincinnati College of Medicine, Cincinnati, Ohio; Pfizer Inc., Groton, Connecticut; Pfizer Inc., New York, New York, USA; Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco, Milan, Italy; Family Medicine Department, University of Sherbrooke, Sherbrooke, Quebec, Canada. Sponsored by Pfizer Inc. Dr. Arnold has received consultancy and speaking fees from Pfizer Inc. (≥ $10,000). Dr. Sarzi-Puttini has received consulting fees, speaking fees, and/or honoraria from Pfizer Inc. Dr. Arsenault has received research funding from and/or participated in a speakers’ bureau for Pfizer Inc. Joseph Driscoll was an employee of inVentiv Health Clinical, which is a paid contractor to Pfizer Inc. for the management of the study and the development of this manuscript. Tahira Khan, Pritha Bhadra Brown, Andrew Clair, Joseph M. Scavone, Joseph Driscoll, Jaren Landen, and Lynne Pauer are fulltime employees of Pfizer Inc. and have stock options with the company. L.M. Arnold, MD, Professor of Psychiatry and Behavioral Neuroscience and Director, Women’s Health Research Program, University of Cincinnati College of Medicine; P. Sarzi-Puttini, MD, Direttore presso U.O.C., Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco; P. Arsenault, MD, Associate Professor, Family Medicine Department, University of Sherbrooke; T. Khan, MD, Senior Manager Clinician, Clinical Sciences, Pfizer Inc.; P. Bhadra Brown, PhD, Director, Statistics, Pfizer Inc.; A. Clair, PhD, Senior Medical Director, US Medical Affairs, Pfizer Inc.; J.M. Scavone, PharmD, Senior Director; J. Driscoll, PharmD, Director; J. Landen, PhD, Director; L. Pauer, MS, Senior Director, Clinical Sciences, Pfizer Inc. Address correspondence to Dr. L.M. Arnold, University of Cincinnati College of Medicine, 260 Stetson St., Suite 3200, Cincinnati, Ohio 45219, USA. E-mail: arnoldlm@ucmail.uc.edu. Accepted for publication March 26, 2015.
Article Information
jrheum.141196
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online June 1, 2015.
Article Versions
- You are currently viewing a Latest version of this article (June 1, 2015 - 05:25).
- View the most recent version of this article
Copyright & Usage
© 2015 The Journal of Rheumatology
Author Information
- Lesley M. Arnold,
- Piercarlo Sarzi-Puttini,
- Pierre Arsenault,
- Tahira Khan,
- Pritha Bhadra Brown,
- Andrew Clair,
- Joseph M. Scavone,
- Joseph Driscoll,
- Jaren Landen and
- Lynne Pauer
- From the Women’s Health Research Program, University of Cincinnati College of Medicine, Cincinnati, Ohio; Pfizer Inc., Groton, Connecticut; Pfizer Inc., New York, New York, USA; Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco, Milan, Italy; Family Medicine Department, University of Sherbrooke, Sherbrooke, Quebec, Canada.
Sponsored by Pfizer Inc. Dr. Arnold has received consultancy and speaking fees from Pfizer Inc. (≥ $10,000). Dr. Sarzi-Puttini has received consulting fees, speaking fees, and/or honoraria from Pfizer Inc. Dr. Arsenault has received research funding from and/or participated in a speakers’ bureau for Pfizer Inc. Joseph Driscoll was an employee of inVentiv Health Clinical, which is a paid contractor to Pfizer Inc. for the management of the study and the development of this manuscript. Tahira Khan, Pritha Bhadra Brown, Andrew Clair, Joseph M. Scavone, Joseph Driscoll, Jaren Landen, and Lynne Pauer are fulltime employees of Pfizer Inc. and have stock options with the company.
L.M. Arnold, MD, Professor of Psychiatry and Behavioral Neuroscience and Director, Women’s Health Research Program, University of Cincinnati College of Medicine; P. Sarzi-Puttini, MD, Direttore presso U.O.C., Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco; P. Arsenault, MD, Associate Professor, Family Medicine Department, University of Sherbrooke; T. Khan, MD, Senior Manager Clinician, Clinical Sciences, Pfizer Inc.; P. Bhadra Brown, PhD, Director, Statistics, Pfizer Inc.; A. Clair, PhD, Senior Medical Director, US Medical Affairs, Pfizer Inc.; J.M. Scavone, PharmD, Senior Director; J. Driscoll, PharmD, Director; J. Landen, PhD, Director; L. Pauer, MS, Senior Director, Clinical Sciences, Pfizer Inc.
Address correspondence to Dr. L.M. Arnold, University of Cincinnati College of Medicine, 260 Stetson St., Suite 3200, Cincinnati, Ohio 45219, USA. E-mail: arnoldlm@ucmail.uc.edu.
Accepted for publication March 26, 2015.
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Efficacy and Safety of Pregabalin in Patients with Fibromyalgia and Comorbid Depression Taking Concurrent Antidepressant Medication: A Randomized, Placebo-controlled Study
Lesley M. Arnold, Piercarlo Sarzi-Puttini, Pierre Arsenault, Tahira Khan, Pritha Bhadra Brown, Andrew Clair, Joseph M. Scavone, Joseph Driscoll, Jaren Landen, Lynne Pauer
The Journal of Rheumatology Jun 2015, jrheum.141196; DOI: 10.3899/jrheum.141196
Efficacy and Safety of Pregabalin in Patients with Fibromyalgia and Comorbid Depression Taking Concurrent Antidepressant Medication: A Randomized, Placebo-controlled Study
Lesley M. Arnold, Piercarlo Sarzi-Puttini, Pierre Arsenault, Tahira Khan, Pritha Bhadra Brown, Andrew Clair, Joseph M. Scavone, Joseph Driscoll, Jaren Landen, Lynne Pauer
The Journal of Rheumatology Jun 2015, jrheum.141196; DOI: 10.3899/jrheum.141196